Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
A031803 will be closed to accrual, effective July 23, 2025 at 4:30 PM ET.